Evidence map›Paper›PMID 33013358›Full record

ArticleFrontiers in pharmacology2020

Endogenous CCN5 Participates in Angiotensin II/TGF-β

Anan Huang, Huihui Li, Chao Zeng, Wanli Chen, Liping Wei, Yue Liu, Xin Qi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases.International journal of molecular sciences · 2021
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anan HuangNankai University School of Medicine, Tianjin, China.
Huihui LiGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Chao ZengDepartment of Cardiology, Tianjin Union Medical Center, Tianjin, China.
Wanli ChenGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Liping WeiDepartment of Cardiology, Tianjin Union Medical Center, Tianjin, China.
Yue LiuDepartment of Cardiology, Tianjin Union Medical Center, Tianjin, China.
Xin QiNankai University School of Medicine, Tianjin, China.
Tianjin People's Hospital · CNTianjin University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant activation of angiotensin II (Ang II) accelerates hypertensive heart failure (HF); this has drawn worldwide attention. The complex Ang II/transforming growth factor (TGF)-β

Indexed as

angiotensin IIcardiac fibrosisCCN5heart failurehypertension

Identifiers

PMID33013358
PMCPMC7494905
OpenAlexW3081761706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.